PRLD.US Prelude Therapeutics Inc

Healthcare Biotechnology USA Stocks
4.07 USD
Close of Nov 18, 2026
1.30 6.83
Market cap
USD 265M
P/E
-
P/B
2.20x
ROE
-39.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PRLD.US undervalued?

Graham number

The Graham number of Prelude Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Prelude Therapeutics Inc fundamental analysis

No fundamental analysis for Prelude Therapeutics Inc yet.

Prelude Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Prelude Therapeutics Inc

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody …

Full company profile